ProCE Banner Activity

BTK Inhibitors in “Other” B-Cell Malignancies

Slideset Download
Download these slides from our ASH 2019 live satellite symposium on safety and optimal use of BTK inhibitors to review the most current clinical data on treating patients with diverse hematologic malignancies.

Released: December 06, 2019

Expiration: December 04, 2020

Share

Faculty

John Pagel

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Loxo Oncology subsidiary of Eli Lilly

Faculty Disclosure

Primary Author

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

John Pagel, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Gilead Sciences and Pharmacyclics